Clinical Trials Logo

Metastases clinical trials

View clinical trials related to Metastases.

Filter by:

NCT ID: NCT00080301 Completed - Breast Cancer Clinical Trials

Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Start date: September 2003
Phase: Phase 3
Study type: Interventional

The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine is better than capecitabine alone in shrinking or slowing the growth of the cancer in women with metastatic breast cancer who are resistant to taxane and received anthracycline chemotherapy. The safety of this treatment will also be studied.

NCT ID: NCT00080262 Completed - Breast Cancer Clinical Trials

Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)

Start date: February 2004
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a taxane, and capecitabine.

NCT ID: NCT00080197 Completed - Breast Neoplasms Clinical Trials

Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients

Start date: February 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if E7070 is an efficacious, safe, and tolerable treatment for patients with metastatic breast cancer who have failed, or could not tolerate, prior treatments with an anthracycline, a taxane, and capecitabine.

NCT ID: NCT00034879 Completed - Carcinoma Clinical Trials

Iressa Expanded Access Program (EAP)

Start date: August 2000
Phase: Phase 3
Study type: Interventional

A program for patients with non small cell lung cancer who may benefit from Iressa, but cannot enter another clinical trial due to them not being eligible, or for whom no trials are available.

NCT ID: NCT00034463 Completed - Cancer Clinical Trials

ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer

Start date: n/a
Phase: Phase 1
Study type: Interventional

This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer.